1294 related articles for article (PubMed ID: 17274383)
21. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
22. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography.
Ferda J; Ferdová E; Baxa J; Kreuzberg B; Daum O; Třeška V; Skalický T
Anticancer Res; 2015 Apr; 35(4):2241-6. PubMed ID: 25862885
[TBL] [Abstract][Full Text] [Related]
23. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
24. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
25. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
Kaya AO; Coskun U; Unlu M; Akdemir UO; Ozdemir NY; Zengin N; Benekli M; Yildiz R; Yaman E; Ozturk B; Gumus M; Uner A; Yamac D; Ucgul E; Buyukberber S
Asian Pac J Cancer Prev; 2008; 9(4):683-6. PubMed ID: 19256759
[TBL] [Abstract][Full Text] [Related]
26. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
[TBL] [Abstract][Full Text] [Related]
27. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
28. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
Ho CL; Yu SC; Yeung DW
J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan.
Lee JE; Jang JY; Jeong SW; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Jin SY; Choi DL
World J Gastroenterol; 2012 Jun; 18(23):2979-87. PubMed ID: 22736922
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT evaluation of lymphoma with renal involvement: comparison with renal carcinoma.
Ye XH; Chen LH; Wu HB; Feng J; Zhou WL; Yang RM; Bu ZB; Ding Y; Guan J; Wang QS
South Med J; 2010 Jul; 103(7):642-9. PubMed ID: 20531045
[TBL] [Abstract][Full Text] [Related]
31. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
32. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
33. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
34. [(18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin].
Hu M; Li MH; Kong L; Liu NB; Yang GR; Yu JM
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):699-701. PubMed ID: 19173915
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
[TBL] [Abstract][Full Text] [Related]
37. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
[TBL] [Abstract][Full Text] [Related]
38. FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma.
Bernstine H; Braun M; Yefremov N; Lamash Y; Carmi R; Stern D; Steinmetz A; Sosna J; Groshar D
Radiology; 2011 Aug; 260(2):503-10. PubMed ID: 21555347
[TBL] [Abstract][Full Text] [Related]
39. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma.
Ho CL; Chen S; Cheng TK; Leung YL
Radiology; 2011 Feb; 258(2):515-23. PubMed ID: 21062922
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
